Proteasome inhibition emerges as a selective amplifier of type III interferon signaling
Type III interferon has long occupied an awkward middle ground in antiviral therapeutics. It delivers immune defense at epithelial surfaces with less systemic toxicity than type I interferon, yet its weaker signaling has limited enthusiasm for clinical translation. This preprint describes a screening strategy designed to change that equation by identifying small molecules that intensify type III interferon JAK-STAT signaling without broadly inflaming the type I pathway.
Investigators built a live-cell high-throughput assay in A549 cells to measure STAT1/STAT2 phosphorylation after cytokine stimulation and screened roughly 8,640 compounds. The screen turned up an unexpected but coherent hit class: proteasome inhibitors. MG132, delanzomib, ixazomib, oprozomib, and bortezomib all potentiated IFN3-induced STAT activation, while showing minimal effect on IFN1 signaling. In a field where cytokine selectivity is often difficult to achieve, the pattern is unusually clean.
The work matters because it points to receptor availability as a controllable bottleneck. Rather than acting downstream on a generic amplification node, proteasome inhibition increased cell-surface IL10Rβ, the limiting receptor subunit for IFN3 signaling. Once that subunit became more abundant on the cell membrane, the receptor complex could transmit a stronger JAK-STAT signal. Antiviral activity rose in parallel and reached levels approaching those seen with IFN1.
A receptor bottleneck, not a blanket immune surge
The biology is more precise than a broad immune boost. IFN3 signals through a receptor system that depends on receptor subunit availability, and IL10Rβ appears to be the scarce component constraining output in this model. By preventing proteasomal turnover, the inhibitors changed the amount of receptor available at the cell surface, effectively releasing a brake on IFN3 responsiveness. The result is a mechanistic explanation for why the same treatment strengthened IFN3 signaling yet left IFN1 largely unchanged.
A single membrane subunit altered the output of an entire antiviral pathway.
The selectivity is important because it suggests the pathway can be tuned without collapsing into nonspecific cytokine activation. IFN1 receptor biology differs from IFN3 receptor biology, and the study shows that proteasome inhibition did not raise IFN1 receptor levels in the same way. Instead, it protected IFNAR2 from late ligand-induced downregulation. Even in that arm of the pathway, the effect looks like preservation of receptor integrity rather than indiscriminate upregulation.
Why proteasome inhibitors changed the response
Proteasomes govern protein turnover, membrane receptor homeostasis, and intracellular signaling dynamics. In this context, blocking proteasomal degradation likely slowed loss of receptor components that would otherwise be internalized or degraded after cytokine engagement. That provides a plausible route to stronger and more durable signaling at the epithelial cell surface, where rapid receptor recycling can determine how much antiviral defense a cell can mount before a virus gains ground.
The screened compounds span drugs with established pharmacology in other settings, including oncology. Their shared feature is not a shared receptor target but a shared capacity to disturb protein degradation. The fact that multiple chemically distinct proteasome inhibitors produced the same direction of effect strengthens the central claim: receptor subunit abundance is a rate-limiting, druggable node in IFN3 signaling.
The therapeutic logic is straightforward. If IFN3 can be made to behave more like IFN1 in antiviral potency while retaining its more favorable safety profile, mucosal antiviral therapy becomes more attractive. Epithelial barriers in the respiratory and gastrointestinal tracts are precisely where a locally strong but systemically restrained interferon response would be most useful. The study does not claim clinical efficacy in patients, but it does identify a mechanistic handle that could be exploited in future drug development.
What the screen can and cannot yet support
The data come from a preprint and from a cell-based system, which keeps the conclusions at the level of mechanistic biology rather than clinical practice. A549 cells offer a useful epithelial model, yet they cannot replicate the full complexity of primary mucosal tissue, inflammatory crosstalk, or drug exposure in vivo. Proteasome inhibition also carries obvious translational caution because these agents are not benign modulators; they have established systemic effects and toxicity profiles that would need to be reconciled with any antiviral intent.
The study’s main strength is architectural rather than descriptive. It shows that a scalable live-cell platform can identify cytokine-selective signaling potentiators, and it does so with a surprising degree of specificity. The screen did not merely rediscover generic immune enhancers. It isolated a family of drugs with a shared and biologically coherent mechanism tied to receptor availability.
For antiviral drug discovery, that matters because it shifts attention away from only finding stronger interferons and toward finding ways to make existing cytokines work better where they are needed most. The immediate next questions are practical ones: whether this receptor-availability strategy translates into primary airway or intestinal epithelia, whether potency can be separated from proteasome inhibitor toxicity, and whether the same approach can be adapted to other cytokine systems with limited signaling strength. Those questions define the boundary between a compelling cell biology result and a future therapeutic program.